Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Malaika Awori"'
Autor:
Domingo Gargallo-Viola, Ilonka Zsolt, Teresa Blazquez, Malaika Awori, Luc Chouinard, Susan Y. Smith, Jorge Ignacio González Borroto, Cristina Tarragó
Publikováno v:
Future microbiology. 13
Aim: Ozenoxacin is a nonfluorinated quinolone antibacterial approved for topical treatment of impetigo. Because quinolones have known chondrotoxic effects in juvenile animals, the potential toxicity of ozenoxacin was assessed in preclinical studies.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89814785adad7878d9734d8dd0d53445
https://pubmed.ncbi.nlm.nih.gov/29745239
https://pubmed.ncbi.nlm.nih.gov/29745239
Autor:
Malaika Awori, Agnès Bénardeau, Rana Samadfam, Luc Chouinard, Elena Sebokova, Robert E. Guldberg, Matthew Blake Wright, Frieder Bauss, Susan Y. Smith
Publikováno v:
Journal of bone and mineral metabolism. 33(6)
Pioglitazone, the peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonist is an effective therapy for type 2 diabetes, but has been associated with increased risk for bone fracture. Preclinical studies suggest that PPAR-α agonists (e.g.,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fa410c1c566ba9790d52722690e5809
https://pubmed.ncbi.nlm.nih.gov/25534548
https://pubmed.ncbi.nlm.nih.gov/25534548
Autor:
Florence Poitout, Todd J. Page, Genevieve Glazier, John L. Vahle, Andre-Jean Lambert, Gary B. Baskin, Lise Bernier, Luc Chouinard, Solomon Haile, Malaika Awori, Daniel G. Rudmann, Pamela Walker
Publikováno v:
Toxicological sciences : an official journal of the Society of Toxicology. 125(2)
LY2541546 is a humanized monoclonal antibody (IgG(4)) that has been optimized for neutralizing activity against sclerostin. In 5-week and 6-month nonclinical safety studies in rats, LY2541546 caused dose-dependent reversible decreases in platelet cou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3791944012dd7087bfff3666555c2590
https://pubmed.ncbi.nlm.nih.gov/22106037
https://pubmed.ncbi.nlm.nih.gov/22106037
Autor:
Malaika Awori, Elena Sebokova, Susan Y. Smith, Frieder Bauss, Matthew Blake Wright, Rana Samadfam, Agnès Bénardeau
Publikováno v:
The Journal of endocrinology. 212(2)
Peroxisome proliferator-activated receptor (PPAR) γ agonists, such as pioglitazone (Pio), improve glycemia and lipid profile but are associated with bone loss and fracture risk. Data regarding bone effects of PPARα agonists (including fenofibrate (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94c478f0a7c0d230a345ace246135d02
https://pubmed.ncbi.nlm.nih.gov/22062085
https://pubmed.ncbi.nlm.nih.gov/22062085
Publikováno v:
Bone. 48:S209-S210
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c0424e0513e1555b761c27a379ff07d5
https://doi.org/10.1016/j.bone.2011.03.481
https://doi.org/10.1016/j.bone.2011.03.481